Spots Global Cancer Trial Database for Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Official Title: Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma

Study ID: NCT00137826

Conditions

Mesothelioma

Interventions

Erlotinib

Bevacizumab

Study Description

Brief Summary: The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

Detailed Description: Each cycle of study treatment lasts 21 days. The patient will take erlotinib by mouth once daily. On day 1 of every cycle, the patient will receive bevacizumab intravenously over a 30-90 minute time period. CT scan(s), MRI(s) and/or x-ray(s) of the cancer site will be performed every 6 weeks (2 cycles) to assess the extent of the response to treatment. Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1, Cycle 2, Cycle 3, and at the end of treatment. At the completion of the treatment a physical exam, vital signs, blood tests, urine tests and standard radiologic testing will be performed. The duration of study depends upon how the patients' mesothelioma responds to treatment as well as how well the patient tolerates the medication.